Technical Analysis for GLSI - Greenwich LifeSciences, Inc.

Grade Last Price % Change Price Change
B 17.03 -2.69% -0.47
GLSI closed down 2.69 percent on Monday, March 18, 2024, on 35 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -2.69%
180 Bullish Setup Bullish Swing Setup -2.69%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.69%
Calm After Storm Range Contraction -2.69%
NR7 Range Contraction -2.69%
Upper Bollinger Band Walk Strength -2.69%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 13 hours ago
Bullish 180 Entry about 13 hours ago
Non-ADX 1,2,3,4 Pullback Entry about 13 hours ago
1,2,3, Pullback Entry about 13 hours ago
Rose Above Previous Day's High about 13 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Greenwich LifeSciences, Inc. Description

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Acid Immunotherapy Surgery Cancer Treatment Breast Cancer Clinical Trial Treatment Of Breast Cancer Her2 Her2/Neu Cancer Center

Is GLSI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 20.75
52 Week Low 7.58
Average Volume 51,616
200-Day Moving Average 10.22
50-Day Moving Average 11.34
20-Day Moving Average 14.57
10-Day Moving Average 16.42
Average True Range 1.68
RSI (14) 62.83
ADX 48.13
+DI 33.58
-DI 12.26
Chandelier Exit (Long, 3 ATRs) 15.71
Chandelier Exit (Short, 3 ATRs) 14.95
Upper Bollinger Bands 19.20
Lower Bollinger Band 9.94
Percent B (%b) 0.77
BandWidth 63.57
MACD Line 1.88
MACD Signal Line 1.63
MACD Histogram 0.2444
Fundamentals Value
Market Cap 218.8 Million
Num Shares 12.8 Million
EPS -0.70
Price-to-Earnings (P/E) Ratio -24.33
Price-to-Sales 0.00
Price-to-Book 12.31
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.23
Resistance 3 (R3) 18.33 18.03 18.03
Resistance 2 (R2) 18.03 17.73 17.98 17.96
Resistance 1 (R1) 17.53 17.54 17.38 17.43 17.90
Pivot Point 17.23 17.23 17.16 17.18 17.23
Support 1 (S1) 16.73 16.93 16.58 16.63 16.16
Support 2 (S2) 16.43 16.74 16.38 16.10
Support 3 (S3) 15.93 16.43 16.03
Support 4 (S4) 15.83